Discover 1,134 paid clinical trials in Norwalk, Connecticut. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,134
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
for
Aortic Regurgitation, Aortic Valve Insufficiency,
Location: New Haven CT, New York NY, New Brunswick NJ,
Sponsor: JenaValve Technology, Inc.
Sex: All
Age: 0+
Code: NCT06608823
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
for
Metastatic Colorectal Cancer
Location: New Haven CT, Cleveland OH, Grand Rapids MI, Houston TX
Sponsor: BioNTech SE
Sex: All
Age: 18+
Code: NCT07079631
Phase 1, Phase 2, Recruiting
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
for
Recurrent Langerhans Cell Histiocytosis,
Location: New Haven CT, The Bronx NY, New Hyde Park NY,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 0 - 22
Code: NCT05828069
Phase 2, Recruiting
Circulating Tumor DNA
for
ER+ Breast Cancer
Location: New Haven CT, The Bronx NY, Boston MA, Baltimore MD,
Sponsor: Yale University
Sex: All
Age: 18+
Code: NCT06923527
Phase 2, Recruiting
Home-based Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for IBS Pain
Get alerts for new trials in your area by subscribing now
A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study
for
Hematopoietic and Lymphatic System Neoplasm,
Location: New Haven CT, The Bronx NY, Hackensack NJ, Brooklyn NY,
Sponsor: Children's Oncology Group
Sex: All
Age: 15 - 20
Code: NCT06410209
Phase 2, Recruiting
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis